MX2023001219A - Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus. - Google Patents
Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus.Info
- Publication number
- MX2023001219A MX2023001219A MX2023001219A MX2023001219A MX2023001219A MX 2023001219 A MX2023001219 A MX 2023001219A MX 2023001219 A MX2023001219 A MX 2023001219A MX 2023001219 A MX2023001219 A MX 2023001219A MX 2023001219 A MX2023001219 A MX 2023001219A
- Authority
- MX
- Mexico
- Prior art keywords
- polypeptide
- seq
- amino acid
- set forth
- nos
- Prior art date
Links
- 241000191940 Staphylococcus Species 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 22
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 22
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 22
- 150000001413 amino acids Chemical class 0.000 abstract 5
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 4
- 230000004927 fusion Effects 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 241000344863 Staphylococcus aureus subsp. aureus COL Species 0.000 abstract 2
- 230000002163 immunogen Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 101100211536 Staphylococcus aureus (strain COL) SACOL2365 gene Proteins 0.000 abstract 1
- 101100227953 Staphylococcus aureus (strain COL) fur gene Proteins 0.000 abstract 1
- 101100404789 Staphylococcus aureus (strain COL) nikC gene Proteins 0.000 abstract 1
- 101100422138 Staphylococcus aureus (strain COL) splC gene Proteins 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
Se proporciona un constructo de fusión de fórmula (I): X-A-ligante-B-Z (I) donde: (1) A y B son idénticos o diferentes y son independientemente: (a) un polipéptido que comprende un polipéptido SACOL0029 según lo expuesto en cualquiera de las secuencias descritas en FIG. 24 (SEC ID NOs: 5 y 121 a 131), un polipéptido SACOL0264 (SEC ID NO: 185), un polipéptido SACOL0442 según lo expuesto en cualquiera de las secuencias descritas en FIG. 22D (SEC ID NOs: 29 y 82 a 92), un polipéptido SACOL0718 (SEC ID NO: 186), un polipéptido SACOL0720 según lo expuesto en cualquiera de las secuencias descritas en FIGs. 23I-J (SEC ID NOs: 11 y 109 a 120), un polipéptido SACOL1353 (SEC ID NO: 187), un polipéptido SACOL1416 (SEC ID NO: 188), un polipéptido SACOL1611 (SEC ID NO: 189), un polipéptido SACOL1867 según lo expuesto en cualquiera de las secuencias descritas en FIG. 25D (SEC ID NOs: 152 a 164), un polipéptido SACOL1912 (SEC ID NO: 43), un polipéptido SACOL1944 (SEC ID NO: 190), un polipéptido SACOL2144 (SEC ID NO: 191), un polipéptido SACOL2365 (SEC ID NO: 192), un polipéptido SACOL2385 (SEC ID NO: 50) o un polipéptido SACOL2599 (SEC ID NO: 193), sobre la base de la nomenclatura genética del genoma COL (SACOL) de Staphylococcus aureus expuesto en la Secuencia de Referencia en el NCBI NC_002951.2; (b) un polipéptido codificado por un gen de un mismo operón que un gen que codifica al polipéptido de (a); (c) un polipéptido que comprende un fragmento inmunogénico de por lo menos 13 aminoácidos consecutivos de (a) o (b); (d) un polipéptido que comprende una secuencia de aminoácidos por lo menos 60% idéntica en su totalidad a la secuencia del polipéptido de cualquiera de (a) a (c); o (e) un polipéptido que comprende una variante inmunogénica que comprende por lo menos 13 aminoácidos consecutivos de cualquiera de (a) a (c); (2) el ligante es una secuencia de aminoácidos de por lo menos un aminoácido o está ausente; (3) X está ausente o es una secuencia de aminoácidos de por lo menos un aminoácido; y (4) Z está ausente o es una secuencia de aminoácidos de por lo menos un aminoácido. Se proporcionan además composiciones y kits que comprenden la fusión y usos de estas fusiones, composiciones y kits.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662411120P | 2016-10-21 | 2016-10-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023001219A true MX2023001219A (es) | 2023-03-03 |
Family
ID=62018642
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019004539A MX2019004539A (es) | 2016-10-21 | 2017-10-20 | Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus. |
| MX2023001219A MX2023001219A (es) | 2016-10-21 | 2019-04-17 | Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019004539A MX2019004539A (es) | 2016-10-21 | 2017-10-20 | Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus. |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US11324815B2 (es) |
| EP (1) | EP3529260A4 (es) |
| JP (2) | JP7181208B2 (es) |
| KR (1) | KR20190082229A (es) |
| CN (1) | CN109843910A (es) |
| AR (1) | AR109847A1 (es) |
| AU (2) | AU2017346974B2 (es) |
| BR (1) | BR112019007796A2 (es) |
| CA (1) | CA3037070A1 (es) |
| CL (1) | CL2019001048A1 (es) |
| CO (1) | CO2019005169A2 (es) |
| CR (1) | CR20190249A (es) |
| DO (1) | DOP2019000102A (es) |
| IL (1) | IL265869A (es) |
| MX (2) | MX2019004539A (es) |
| MY (1) | MY195369A (es) |
| NZ (1) | NZ751880A (es) |
| PE (1) | PE20191320A1 (es) |
| PH (1) | PH12019500843A1 (es) |
| RU (2) | RU2022100889A (es) |
| SG (2) | SG10201912431XA (es) |
| TW (1) | TW201819402A (es) |
| UY (1) | UY37448A (es) |
| WO (1) | WO2018072031A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113777317A (zh) * | 2020-06-09 | 2021-12-10 | 首都医科大学附属北京世纪坛医院 | 尿液主穹隆蛋白及其多肽片段在烧伤中的应用 |
| WO2022125928A1 (en) * | 2020-12-11 | 2022-06-16 | Bayer Animal Health Gmbh | Methods and compositions for improved production of an antigen for use in an s. aureus vaccine |
| US12161970B1 (en) | 2024-08-09 | 2024-12-10 | Jiaxing Research Institute, Zhejiang University | CO2 desorption system suitable for limited space in complex sailing region and flexible control method |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0187702B1 (en) | 1985-01-07 | 1990-03-14 | Syntex (U.S.A.) Inc. | N-(omega,omega-1-dialkoxy)- and n-(omega,omega-1-dialkenoxy)-alk-1-yl-n,n,n-trisubstituted ammonium surfactants, their preparation and pharmaceutical formulations containing them |
| US6228844B1 (en) | 1991-11-12 | 2001-05-08 | Vical Incorporated | Stimulating vascular growth by administration of DNA sequences encoding VEGF |
| US7060458B1 (en) | 1997-08-14 | 2006-06-13 | Wyeth | Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics |
| US6380370B1 (en) | 1997-08-14 | 2002-04-30 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics |
| US6833134B2 (en) | 2000-06-12 | 2004-12-21 | University Of Saskacthewan | Immunization of dairy cattle with GapC protein against Streptococcus infection |
| GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
| AU2003295520B8 (en) | 2002-11-12 | 2011-05-19 | The Brigham And Women's Hospital, Inc. | Polysaccharide vaccine for Staphylococcal infections |
| CN1569893A (zh) | 2003-07-21 | 2005-01-26 | 中国人民解放军军事医学科学院基础医学研究所 | 金葡菌毒力因子调控蛋白的抗原表位及其模拟表位和用途 |
| RU2419628C2 (ru) | 2004-09-22 | 2011-05-27 | ГлаксоСмитКлайн Байолоджикалз с.а. | Иммуногенная композиция для применения в вакцинации против стафилококков |
| CA2583121A1 (en) * | 2004-10-21 | 2007-01-04 | Wyeth | Immunogenic compositions of staphylococcus epidermidis polypeptide antigens |
| KR100729954B1 (ko) | 2004-12-01 | 2007-06-20 | 주식회사 엘지생명과학 | Ｓｅｃ１ 변이 단백질의 제형 및 그것의 제형화 방법 |
| WO2008152447A2 (en) | 2006-10-30 | 2008-12-18 | The University Of Western Ontario | Staphylococcus aureus specific anti-infectives |
| US9932373B2 (en) | 2009-03-23 | 2018-04-03 | Epitopix, Llc | Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use |
| CA3154626A1 (en) | 2009-04-14 | 2010-10-21 | Glaxosmithkline Biologicals S.A. | Compositions for immunising against staphylococcus aureus |
| PT2547361T (pt) | 2010-03-17 | 2020-12-07 | Socpra Sciences Et Genie Sec | Componentes de vacina bacteriana de staphylococcus aureus e suas utilizações |
| WO2012177658A2 (en) | 2011-06-19 | 2012-12-27 | New York Univeristy | Methods of treating and preventing staphylococcus aureus infections and associated conditions |
-
2017
- 2017-10-20 TW TW106136089A patent/TW201819402A/zh unknown
- 2017-10-20 AU AU2017346974A patent/AU2017346974B2/en not_active Ceased
- 2017-10-20 EP EP17863203.0A patent/EP3529260A4/en active Pending
- 2017-10-20 NZ NZ751880A patent/NZ751880A/en unknown
- 2017-10-20 CN CN201780064991.1A patent/CN109843910A/zh active Pending
- 2017-10-20 BR BR112019007796A patent/BR112019007796A2/pt not_active IP Right Cessation
- 2017-10-20 SG SG10201912431XA patent/SG10201912431XA/en unknown
- 2017-10-20 PE PE2019000844A patent/PE20191320A1/es unknown
- 2017-10-20 KR KR1020197014191A patent/KR20190082229A/ko not_active Abandoned
- 2017-10-20 AR ARP170102922A patent/AR109847A1/es not_active Application Discontinuation
- 2017-10-20 SG SG11201901483QA patent/SG11201901483QA/en unknown
- 2017-10-20 MX MX2019004539A patent/MX2019004539A/es unknown
- 2017-10-20 WO PCT/CA2017/051253 patent/WO2018072031A1/en not_active Ceased
- 2017-10-20 JP JP2019542759A patent/JP7181208B2/ja active Active
- 2017-10-20 RU RU2022100889A patent/RU2022100889A/ru unknown
- 2017-10-20 RU RU2019115303A patent/RU2766354C2/ru active
- 2017-10-20 MY MYPI2019002159A patent/MY195369A/en unknown
- 2017-10-20 CR CR20190249A patent/CR20190249A/es unknown
- 2017-10-20 US US16/337,457 patent/US11324815B2/en active Active
- 2017-10-20 CA CA3037070A patent/CA3037070A1/en active Pending
- 2017-10-20 UY UY0001037448A patent/UY37448A/es unknown
-
2019
- 2019-04-07 IL IL265869A patent/IL265869A/en unknown
- 2019-04-16 PH PH12019500843A patent/PH12019500843A1/en unknown
- 2019-04-17 MX MX2023001219A patent/MX2023001219A/es unknown
- 2019-04-17 CL CL2019001048A patent/CL2019001048A1/es unknown
- 2019-04-17 DO DO2019000102A patent/DOP2019000102A/es unknown
- 2019-05-21 CO CONC2019/0005169A patent/CO2019005169A2/es unknown
-
2022
- 2022-04-05 US US17/713,683 patent/US20220288183A1/en not_active Abandoned
- 2022-06-28 AU AU2022204585A patent/AU2022204585A1/en not_active Abandoned
- 2022-11-16 JP JP2022183528A patent/JP2023025066A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016034981A5 (es) | ||
| EA201991440A1 (ru) | ТЕРМОСТАБИЛЬНЫЕ НУКЛЕАЗЫ Cas9 | |
| CY1118029T1 (el) | Βακτηριοφαγος ή λυτικη πρωτεϊνη που προερχεται απο το βακτηριοφαγο που ειναι αποτελεσματικα για την αντιμετωπιση βιομεμβρανης απο staphylococcus aureus | |
| AR086078A1 (es) | Proteinas de fusion y vacunas de combinacion | |
| WO2009024327A3 (en) | New proteins for use in human and animal staphylococcus infections | |
| WO2015107363A3 (en) | Mycobacterial antigen composition | |
| MX2023001219A (es) | Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus. | |
| IN2014DN06652A (es) | ||
| JP2015533791A5 (es) | ||
| MX384834B (es) | Novedoso bacteriófago esc-cop-1 de e. coli tipo f18 productora de toxina shiga y su uso para inhibir la proliferación de e. coli tipo f18 productora de toxina shiga | |
| WO2016130628A8 (en) | Griffithsin mutants | |
| MY195726A (en) | Steviol Glycoside Transport | |
| JP2010265269A5 (es) | ||
| AR060960A1 (es) | Peptido, polinucleotico, secuencia celula transgenica, huesped viral, celula huesped, vector de expresion, uso y metodo de antagonistas de alta afinidad de quimioquinas elr- cxc | |
| MX2009007261A (es) | Vacuna de peptido foxp3. | |
| JP2019505567A5 (es) | ||
| MY187334A (en) | Xylanase | |
| KR20180084352A (ko) | 돌돔 유래의 신규한 피스시딘 펩티드 및 이의 용도 | |
| EP4043558A3 (en) | Kaurenoic acid hydroxylases | |
| JP2013542942A5 (es) | ||
| EA201890232A1 (ru) | Новые микроорганизмы и их применение в сельском хозяйстве | |
| AR053372A1 (es) | Proteinas inmunologicas de lawsonia intracellularis | |
| JP2019531100A5 (es) | ||
| NO20085201L (no) | Rekombinante novirhabdoviruser og deres anvendelse | |
| JP2015129652A5 (es) |